Amgen (BUE:AMGN) Accumulated Depreciation : ARS-3,540,688 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Amgen Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Amgen's quarterly accumulated depreciation stayed the same from Jun. 2023 (ARS0 Mil) to Sep. 2023 (ARS0 Mil) but then increased from Sep. 2023 (ARS0 Mil) to Dec. 2023 (ARS-3,540,688 Mil).

Amgen's annual accumulated depreciation increased from Dec. 2021 (ARS-888,510 Mil) to Dec. 2022 (ARS-1,556,295 Mil) and increased from Dec. 2022 (ARS-1,556,295 Mil) to Dec. 2023 (ARS-3,540,688 Mil).

Amgen Accumulated Depreciation Historical Data

The historical data trend for Amgen's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Accumulated Depreciation Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-499,527.97

-730,548.23

-888,510.00

-1,556,294.91

-3,540,688.00

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated Depreciation	Get a 7-Day Free Trial															-1,556,294.91	-	-	-	-3,540,688.00

Amgen Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Amgen Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Amgen's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.